- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04804033
A Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
March 20, 2024 updated by: Pfizer
A Phase 2/3 Randomized, Double-Blind, Placebo- Controlled Study to Evaluate the Efficacy and Safety of Oral Zavegepant in Migraine Prevention
The purpose of this is study is to compare the efficacy of BHV-3500 (zavegepant) to placebo as a preventive treatment for migraine, as measured by the reduction in the number of migraine days per month.
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
538
Phase
- Phase 2
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Pfizer CT.gov Call Center
- Phone Number: 1-800-718-1021
- Email: ClinicalTrials.gov_Inquiries@pfizer.com
Study Locations
-
-
Arizona
-
Phoenix, Arizona, United States, 85004
- Xenoscience, Inc
-
Tucson, Arizona, United States, 85710
- Tucson Neuroscience Research
-
-
California
-
Canoga Park, California, United States, 91303
- Hope Clinical Research
-
Colton, California, United States, 92324
- Axiom Research, LLC
-
Encino, California, United States, 91316
- Wr-Pri, Llc
-
La Mesa, California, United States, 91942
- eStudySite
-
Lemon Grove, California, United States, 91945
- Synergy San Diego
-
Long Beach, California, United States, 90806
- Collaborative Neuroscience Research, LLC.
-
Los Angeles, California, United States, 90048
- Clinical Research Institute
-
Newport Beach, California, United States, 92660
- Wr-Pri, Llc
-
San Diego, California, United States, 92103
- Artemis Institute for Clinical Research
-
Sherman Oaks, California, United States, 91403
- California Neuroscience Research Medical Group, Inc.
-
-
Connecticut
-
Hamden, Connecticut, United States, 06517
- CMR of Greater New Haven, LLC
-
Stamford, Connecticut, United States, 06905
- Ki Health Partners, LLc, dba New England Institute for Clinical Research
-
Waterbury, Connecticut, United States, 06708
- Chase Medical Research, LLC
-
-
Florida
-
Boca Raton, Florida, United States, 33428
- Neurology Offices of South Florida
-
Edgewater, Florida, United States, 32132
- Complete Health Research
-
Gainesville, Florida, United States, 32607
- Sarkis Clinical Trials
-
Jacksonville, Florida, United States, 32256
- Clinical Neuroscience Solutions, Inc.
-
Lake City, Florida, United States, 32055
- Multi-Specialty Research Associates, Inc.
-
Miami, Florida, United States, 33155
- AppleMed Research Group, LLC
-
Miami, Florida, United States, 33176
- Brainstorm Research
-
Miami, Florida, United States, 33176
- The Neurology Research Group
-
Miami, Florida, United States, 33126
- AppleMed Research Group, LLC
-
Orlando, Florida, United States, 32801
- Clinical Neuroscience Solutions, Inc.
-
Ormond Beach, Florida, United States, 32174
- Complete Health Research
-
Pembroke Pines, Florida, United States, 33026
- Ideal Clinical Research
-
Pompano Beach, Florida, United States, 33060
- Clinical Research Center of Florida
-
Saint Petersburg, Florida, United States, 33709
- Accel Research Sites Network - St. Petersburg Clinical Research Unit
-
South Miami, Florida, United States, 33143
- Clin-Med Research & Development LLC
-
Tampa, Florida, United States, 33613
- Forcare Clinical Research
-
Tampa, Florida, United States, 33634
- JSV Clinical Research Study Inc
-
-
Georgia
-
Decatur, Georgia, United States, 30030
- iResearch Atlanta LLC
-
Decatur, Georgia, United States, 30030
- CenExel iResearch, LLC
-
-
Illinois
-
Chicago, Illinois, United States, 60607
- Cedar Crosse Research Center
-
Gurnee, Illinois, United States, 60031
- Clinical Investigation Specialists, Inc
-
Gurnee, Illinois, United States, 60031
- Clinical Investigation Specialists, Inc.
-
-
Indiana
-
Evansville, Indiana, United States, 47714
- MediSphere Medical Research Center, LLC
-
Evansville, Indiana, United States, 47714
- MediSphere Medical Research Center, LLC.
-
-
Iowa
-
Sioux City, Iowa, United States, 51106
- Meridian Clinical Research, LLC
-
-
Kansas
-
El Dorado, Kansas, United States, 67042
- Alliance for Multispecialty Reseach, LLC
-
Newton, Kansas, United States, 67114
- Alliance for Multispecialty Research, LLC
-
Overland Park, Kansas, United States, 66211
- Kansas Institute of Research
-
Overland Park, Kansas, United States, 66210
- Collevtive Medical Research
-
-
Kentucky
-
Lexington, Kentucky, United States, 40503
- The Research Group of Lexington, LLC
-
Lexington, Kentucky, United States, 40503
- The Research Group of Lexington, Llc.
-
Louisville, Kentucky, United States, 40213
- L-MARC Research Center
-
-
Louisiana
-
Chalmette, Louisiana, United States, 70043
- Crescent City Headache and Neurology Center
-
New Orleans, Louisiana, United States, 70124
- Delricht Research
-
New Orleans, Louisiana, United States, 70119
- Alliance for Multispecialty Research, LLC.
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02131
- Boston Clinical Trials
-
Foxboro, Massachusetts, United States, 02035
- Neurology Center of New England P.C.
-
Marlborough, Massachusetts, United States, 01752
- Community Clinical Research Network Inc
-
Waltham, Massachusetts, United States, 02451
- MedVadis Research Corporation
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48104
- Michigan Head Pain & Neurological Institute
-
Rochester, Michigan, United States, 48307
- Romedica LLC
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
- Alliance for Multispecialty Reseach, LLC
-
Saint Peters, Missouri, United States, 63303
- StudyMetrix Research
-
Springfield, Missouri, United States, 65810
- Clinvest Research, LLC
-
Springfield, Missouri, United States, 65807
- Clinvest Research, LLC
-
-
Nebraska
-
Norfolk, Nebraska, United States, 68701
- Meridian Clinical Research, LLC
-
-
Nevada
-
Las Vegas, Nevada, United States, 89109
- Excel Clinical Research
-
Las Vegas, Nevada, United States, 89118
- Wr-Crcn, Llc
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87102
- Albuquerque Clinical Trials, Inc.
-
-
New York
-
Amherst, New York, United States, 14226
- Dent Neurosciences Research Center, Inc.
-
Bronx, New York, United States, 10461
- Montefiore Medical Center
-
Manlius, New York, United States, 13104
- Central New York Clinical Research
-
New York, New York, United States, 10017
- Fieve Clinical Research, Inc
-
New York, New York, United States, 10003
- New York Neurology Associates
-
Port Jefferson Station, New York, United States, 11776
- North Suffolk Neurology, PC
-
Williamsville, New York, United States, 14221
- Upstate Clinical Research Associates, LLC
-
-
North Carolina
-
Greensboro, North Carolina, United States, 27405
- Headache Wellness Center
-
Raleigh, North Carolina, United States, 27612
- M3 Wake Research, Inc.
-
Raleigh, North Carolina, United States, 27609
- Accellacare
-
Shelby, North Carolina, United States, 28150
- Carolina Research Center, Inc.
-
Wilmington, North Carolina, United States, 28401
- Accellacare
-
-
Ohio
-
Cincinnati, Ohio, United States, 45212
- CTI Clinical Research Center
-
Cincinnati, Ohio, United States, 45215
- Wellnow Urgent Care
-
Columbus, Ohio, United States, 43214
- Hometown Urgent Care and Research
-
Columbus, Ohio, United States, 43214
- Wellnow Urgent Care and Research
-
Dayton, Ohio, United States, 45424
- Hometown Urgent Care and Research
-
Dayton, Ohio, United States, 45424
- Wellnow Urgent Care and Research
-
North Canton, Ohio, United States, 44720
- Neuro-Behavioral Clinical Research, Inc.
-
Troy, Ohio, United States, 45373
- Wellnow Urgent Care and Research
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73134
- Hightower Clinical
-
-
Oregon
-
Portland, Oregon, United States, 97210
- Summit Headlands LLC, dba Summit Research
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, United States, 19114
- Clinical Research Philadelphia, LLC
-
Pittsburgh, Pennsylvania, United States, 15236
- Preferred Primary Care Physicians, Inc.
-
Uniontown, Pennsylvania, United States, 15401
- Preferred Primary Care Physicians
-
West Reading, Pennsylvania, United States, 19611
- Reading Hospital Clinical Trials Office
-
West Reading, Pennsylvania, United States, 19611
- Tower Health Medical Group - Neurology
-
-
South Carolina
-
North Charleston, South Carolina, United States, 29405
- Coastal Carolina Research Center
-
-
Tennessee
-
Bristol, Tennessee, United States, 37620
- Internal Medicine and Pediatric Associates of Bristol, PC
-
Bristol, Tennessee, United States, 37620
- Accellacare (Administrative Only)
-
Chattanooga, Tennessee, United States, 37421
- WR-Clinsearch, LLC
-
Franklin, Tennessee, United States, 37067
- KCA Neurology, PLLC
-
Memphis, Tennessee, United States, 38119
- Clinical Neuroscience Solutions, Inc.
-
-
Texas
-
Austin, Texas, United States, 78731
- FutureSearch Trials of Neurology
-
Dallas, Texas, United States, 75231
- FutureSearch Trials of Dallas, LP
-
Frisco, Texas, United States, 75034
- North Texas Institute of Neurology and Headache
-
Houston, Texas, United States, 77081
- Texas Center for Drug Development, Inc.
-
Lake Jackson, Texas, United States, 77566
- Red Star Research. LLC
-
Lampasas, Texas, United States, 76550
- FMC Science
-
Lampasas, Texas, United States, 76550
- Radiance Clinical Research
-
Tomball, Texas, United States, 77375
- DM Clinical Research
-
-
Utah
-
Salt Lake City, Utah, United States, 84107
- Wasatch Clinical Research , LLC(Administrative Location)
-
-
Virginia
-
Charlottesville, Virginia, United States, 22911
- Charlottesville Medical Research Center, LLC
-
Newport News, Virginia, United States, 23606
- Health Research of Hampton Roads, Inc.
-
Norfolk, Virginia, United States, 23502
- Meridian Clinical Research, LLC
-
-
Washington
-
Bellevue, Washington, United States, 98007
- Northwest Clinical Research Center
-
Seattle, Washington, United States, 98105
- Seattle Women's: Health, Research, Gynecology
-
Seattle, Washington, United States, 98105
- Seattle Clinical Research Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Description
Inclusion Criteria:
Subject has at least 1 year history of migraine (with or without aura) consistent with a diagnosis according to the International Classification of
Headache Disorders, 3rd Edition, including the following:
- Age of onset of migraines prior to 50 years of age
- Migraine attacks, on average, lasting 4 - 72 hours if untreated
- Per subject report, at least 15 headache days per month, at lest 8 migraine days per month, and at least 1 headache-free day per month within the last 3 months prior to the Screening Visit
- Eight or more migraine days during the Observation Period
- 15 or more headache days during the Observation Period
- One or more non-headache days during the Observation Period
- Ability to distinguish migraine attacks from tension/cluster headaches
- Subjects on prophylactic migraine medication are permitted to remain on 1 medication with possible migraine-prophylactic effects if the dose has been stable for at least 3 months prior to the Screening Visit, and the dose is not expected to change during the course of the study.
Exclusion Criteria:
- Subject with a history of HIV disease
- Subject history with current evidence of uncontrolled, unstable or recently diagnosed cardiovascular disease, such as ischemic heart disease, coronary artery vasospasm, and cerebral ischemia. Subjects with Myocardial Infarction (MI), Acute Coronary Syndrome (ACS), Percutaneous Coronary Intervention (PCI), cardiac surgery, stroke or transient ischemic attack (TIA) during the 6 months prior to screening
- Uncontrolled hypertension (high blood pressure), or uncontrolled diabetes (however subjects can be included who have stable hypertension and/or diabetes for at least 3 months prior to screening).
- Subjects with major depressive episode or anxiety disorder which require more than 1 daily medication for each disorder or subjects with a major depressive episode within the last 12 months. Medications to treat major depressive disorder or an anxiety disorder must have been at a stable dose for at least 3 months prior to the Screening Visit.
- Subjects with active chronic pain syndromes, other pain syndromes (including trigeminal neuralgia), psychiatric conditions, dementia, or significant neurological disorders (other than migraine) that, in the Investigator's opinion interfere with study assessments of safety or efficacy.
- Subject has a history of gastric, or small intestinal surgery (including Gastric Bypass, Gastric Banding, Gastric Sleeve, Gastric Balloon, etc.), or has disease or condition (e.g. chronic pancreatitis, ulcerative colitis, etc.) that causes malabsorption.
- Body mass index > 33 kg/m2
- History of gallstones or cholecystectomy.
- The subject has a history or current evidence of any unstable medical conditions (e.g., history of congenital heart disease or arrhythmia, known or suspected infection, hepatitis B or C, or cancer) that, in the investigator's opinion, would expose them to undue risk of a significant adverse event (AE) or interfere with assessments of safety or efficacy during the course of the trial
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Sequential Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: BHV-3500 200mg
Zavegepant 200mg oral soft gel capsule.
|
BHV-3500 (zavegepant) softgel capsule.
|
Placebo Comparator: Placebo 200mg
Matching placebo 200mg oral soft gel capsule.
|
Matching placebo softgel capsule.
|
Active Comparator: BHV-3500 100mg
Zavegepant 100mg oral soft gel capsule.
|
BHV-3500 (zavegepant) softgel capsule.
|
Placebo Comparator: Placebo 100mg
Matching placebo 100mg oral soft gel capsule.
|
Matching placebo softgel capsule.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of zavegepant compared to placebo as a preventive treatment for migraine
Time Frame: Number of migraine during weeks 1 to 12
|
Measured by the mean reduction from baseline (i.e., Observation Phase) in the number of migraine days per month over the entire Double-blind Treatment Phase.
|
Number of migraine during weeks 1 to 12
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Efficacy of zavegepant compared to placebo with the number of subjects that had a ≥ 50% reduction from Observational Phase.
Time Frame: Number of migraine days during weeks 1 to 12
|
Measured by the number of moderate to severe migraine days per month over the entire double-blind treatment phase.
|
Number of migraine days during weeks 1 to 12
|
Efficacy of zavegepant to placebo on mean reduction from Observational Phase.
Time Frame: Number of migraine days during per month during weeks 9 to 12
|
Measured by the number of migraine days in the last 4 weeks of the Double-Blind Treatment Phase.
|
Number of migraine days during per month during weeks 9 to 12
|
Efficacy of zavegepant to placebo on mean reduction from Observational Phase.
Time Frame: Number of migraine days per month during weeks 1 to 4
|
Measured by the number of migraine days per month in the first 4 weeks of the Double-Blind Treatment Phase.
|
Number of migraine days per month during weeks 1 to 4
|
Efficacy of zavegepant to placebo in the mean number of acute migraine specific medication days per month.
Time Frame: Number of migraine days per month during weeks 1 to 12
|
Measured by the number of acute migraine specific medication days over the entire Double-Blind Treatment Phase.
|
Number of migraine days per month during weeks 1 to 12
|
Mean Change From Baseline in the Migraine Specific Quality of Life (MSQoL) Role Function-Restrictive Domain Score at Week 12 of the DBT Phase.
Time Frame: Week 12 of the double-blind treatment phase.
|
The change from baseline is calculated as the MSQoL restrictive role function domain score at Week 12 of the DBT phase minus the MSQoL restrictive role function domain score at baseline.
|
Week 12 of the double-blind treatment phase.
|
Mean Change From Baseline in the Migraine Disability Assessment (MIDAS) Total Score at Week 12 of the DBT Phase.
Time Frame: Week 12 of the double-blind treatment phase.
|
The change from baseline is calculated as the MIDAS total score at Week 12 of the DBT phase minus the MIDAS total score at baseline.
|
Week 12 of the double-blind treatment phase.
|
Evaluate the safety and tolerability of zavegepant.
Time Frame: From Baseline through Week 12
|
This will be evaluated by the number of participants with treatment related adverse events by severity measured as mild, moderate, or severe.
|
From Baseline through Week 12
|
The frequency of ALT or AST elevations > 3x ULN, concurrently with bilirubin elevations > 2x ULN in subjects treated with zavegepent during the double-blind and open label phases.
Time Frame: From Baseline through Week 12
|
From Baseline through Week 12
|
|
The frequency of hepatic related adverse events.
Time Frame: From Baseline through Week 12
|
Measured by discontinuations in subjects treated with zavegepant due to elevated Liver Function Tests during the double-blind and open label phases
|
From Baseline through Week 12
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
March 26, 2021
Primary Completion (Estimated)
March 20, 2024
Study Completion (Estimated)
March 20, 2024
Study Registration Dates
First Submitted
March 5, 2021
First Submitted That Met QC Criteria
March 17, 2021
First Posted (Actual)
March 18, 2021
Study Record Updates
Last Update Posted (Actual)
March 21, 2024
Last Update Submitted That Met QC Criteria
March 20, 2024
Last Verified
March 1, 2024
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- BHV3500-302
- C5301006 (Other Identifier: Alias Study Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
Pfizer will provide access to individual de-identified participant data and related study documents (e.g.
protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Migraine
-
Austrian Migraine Registry CollaborationMedical University of Vienna; Medical University Innsbruck; Austrian Headache...RecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineAustria
-
Tonix Pharmaceuticals, Inc.PremierCompletedChronic Migraine | Chronic Migraine, Headache | Chronic Migraine Without Aura | Aura MigraineUnited States
-
Harvard University Faculty of MedicineBrigham and Women's Hospital; Palmer Center for Chiropractic Research (PCCR)CompletedMigraine | Migraine Disorders | Migraine Without Aura | Migraine With Aura | Migraine, ClassicUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
CoolTech LLCTerminatedMigraine | Migraine Without Aura | Migraine With Aura | Episodic MigraineUnited States
-
University of FlorenceAzienda Ospedaliera Città della Salute e della Scienza di Torino; University... and other collaboratorsRecruitingMigraine | Chronic Migraine | Migraine Without Aura | Migraine With AuraItaly
-
Notre-Dame Hospital, Montreal, Quebec, CanadaAllerganCompletedChronic Migraine | Migraine Without Aura | Migraine With AuraCanada
-
Glostrup University Hospital, CopenhagenUnknownChronic Migraine | Migraine Without Aura | Migraine With AuraDenmark
-
Fondazione I.R.C.C.S. Istituto Neurologico Carlo...CompletedMigraine With Aura | Migraine in ChildrenItaly
-
The Cleveland ClinicWithdrawnMigraine | Migraine Disorders | Headache Disorders, Primary | Migraine Headache | Migraine Without Aura | Migraine With Aura | Headache, MigraineUnited States
Clinical Trials on BHV-3500 (zavegepant)
-
PfizerCompletedAcute MigraineUnited States
-
PfizerTerminatedCOVID-19 InfectionUnited States
-
PfizerCompleted
-
PfizerRecruitingMigraineTaiwan, China, Korea, Republic of
-
Biohaven Pharmaceuticals, Inc.Enrolling by invitationObsessive Compulsive DisorderCanada, United States, Spain, United Kingdom, Italy, Netherlands
-
PfizerCompleted
-
PfizerCompleted